Do patients adhere to over-the-counter artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Cohen, Jessica L ^a,b   Yavuz, Elif ^a   Morris, Alexandra ^c   Arkedis, Jean ^d   Sabot, Oliver ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BROOKINGS INSTITUTION   (United States)

^c CLINTON HEALTH ACCESS INITIATIVE   (United States)

^d RESULTS FOR DEVELOPMENT INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; NON PRESCRIPTION DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BED NET; CHILD; FEMALE; FOLLOW UP; GENDER; HEALTH BEHAVIOR; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; MARRIAGE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PROFESSIONAL PRACTICE; QUESTIONNAIRE; SCHOOL CHILD; SELF REPORT; SOCIAL STATUS; UGANDA; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; INTERVENTION STUDY; MALARIA FALCIPARUM; PARASITOLOGY; PHARMACY; PHYSIOLOGY; PLASMODIUM FALCIPARUM; RANDOMIZATION;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HUMANS; INTERVENTION STUDIES; MALARIA, FALCIPARUM; MALE; PATIENT COMPLIANCE; PHARMACIES; PLASMODIUM FALCIPARUM; RANDOM ALLOCATION; UGANDA;

EID: 84858722504     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-83     Document Type: Article

References (49)

1. World Health Organization, World Malaria Report 2010 http://www.who.int/ malaria/world-malaria-report-2010/en/index.html Accessed 15 November 2011
2. Artemisinin resistance: Current status and scenarios for containment. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, von Seidlein L, Nat Rev Microbiol 2010 8 272 280 20208550
3. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phao Phyo A, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
4. Efficacy of arthemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, Socheat D, Fandeurs T, Annerberg A, Christophel EM, Ringwald P, Trop Med Int Health 2006 11 1800 1807 10.1111/j.1365-3156.2006. 01739.x 17176344 (Pubitemid 44813874)
5. Effectiveness of antimalarial drugs. Baird JK, N Engl J Med 2005 352 1565 1577 10.1056/NEJMra043207 15829537 (Pubitemid 40517097)
6. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW, Lancet Infect Dis 2003 3 349 358 10.1016/S1473-3099(03)00657-1 12781507 (Pubitemid 36718014)
7. AMFm Summary Report on Co-payments. The Global Fund to Fight AIDS, TB and Malaria, 2011 http://portfolioreports.cloudapp.net/AMFm-Summary.aspx Accessed 15 November 2011
8. Health Action International, Retail prices of ACT co-paid by the AMFm and other antimalarial medicines: Ghana, Kenya, Madagascar, Nigeria, Tanzania and Uganda 2011
9. Got ACT? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabie CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D, Malar J 2011 10
10. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. Smith N, Obala A, Simiyu C, Menya D, Khwa-Otsyula B, Prudhomme O'Meara W, Malar J 2011 10 316 10.1186/1475-2875-10-316 22029829
11. Retail sector distribution chains for malaria treatment in the developing world: a review of the literature. Patouillard E, Hanson K, Goodman C, Malar J 2010 9 50 10.1186/1475-2875-9-50 20149246
12. Cohen J, Dupas P, Schaner S, Price subsidies, diagnostic tests and the demand for malaria treatment: evidence from a randomized controlled trial 2011 J-PAL Working Paper. http://www.povertyactionlab.org/. Accessed: 16 November 2011
13. Willingness and ability to pay for artemisinin-based combination therapy in rural Tanzania. Saulo EC, Forsberg BC, Premji Z, Montgomery S, Bjorkman A, Malar J 2008 7 227 10.1186/1475-2875-7-227 18976453
14. Differences in willingness to pay for artemisinin-based combinations or monotherapy: experiences from the United Republic of Tanzania. Wiseman V, Onwujekwe O, Matovu F, Mutabingwa TK, Whitty CJM, Bull World Health Organ 2005 83 845 852 16302041 (Pubitemid 41624870)
15. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Whitty JM, Chandler C, Ansah E, Leslie T, Staedke SG, Malar J 2008 7 Suppl 1 7 10.1186/1475-2875-7-S1-S7 19091041
16. Universal access to malaria medicines: innovation in financing and delivery. Adeyi O, Atun R, Lancet 2010 376 1869 1871 10.1016/S0140-6736(10) 61189-0 20940074
17. World Health Organization, Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010 2010 http://whqlibdoc.who.int/publications/2010/ 9789241500470-eng.pdf Accessed: 16 November 2011
18. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Yeung S, Avornpinyo WP, Mills AJ, White NJ, Am J Trop Med Hyg 2004 71 179 186 15331836 (Pubitemid 39121321)
19. th Meeting, 2-4 December, 2009. Malaria Consortium, 2010 Submitted by The Global Malaria Programme (GMP). http://www.malariaconsortium.org/userfiles/file/Resistance-Resources/ RBM%20Strategy%20on%20Antimalarial%20Drug%20Resistance.pdf. Accessed: May 9, 2011
20. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NPJ, Malar J 2009 8 253 10.1186/1475-2875-8-253 19906307
21. The de novo selection of drug-resistant malaria parasites. White NJ, Pongtavornpinyo W, Proceedings Biological Sciences 2003 270 545 554 10.1098/rspb.2002.2241 (Pubitemid 36308233)
22. Antimalarial drug resistance and combination therapy. White NJ, Philosophical Transactions of the Royal Society, Series B, Biological Sciences 1999 354 739 749 10.1098/rstb.1999.0426
23. Artesunate combinations for treatment of malaria: meta-analysis. Aduik M, Babiker A, Garner P, Olliaro P, Taylor W, White NJ, International Artemisinin Study Group, Lancet 2004 363 9 17 14723987 (Pubitemid 38076919)
24. How do patients use antimalarial drugs? A review of the evidence. Yeung S, White NJ, Trop Med Int Health 2005 10 121 138 10.1111/j.1365-3156.2004.01364. x 15679555 (Pubitemid 40269162)
25. Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts. Lawford H, Zurovac D, O'Reilly L, Hoibak S, Cowley A, Munga S, Vulule J, Juma E, Snow R, Allan R, Kenya Malar J 2011 10 281
26. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, Genton B, Malar J 2010 9 48 10.1186/1475-2875-9-48 20149235
27. Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone. Gerstl S, Dunkley S, Mukhtar A, Baker S, Jacob M, Trans R Soc Trop Med Hyg 2010 104 328 335 10.1016/j.trstmh.2009.12.008 20129636
28. Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Beer N, Ali A, Rotllant G, Abass AK, Omari R, Al-mafazy A, Björkman A, Källander K, Trop Med Int Health 2009 14 766 774 10.1111/j.1365-3156.2009.02289.x 19549001
29. Factors related to compliance to anti-malarial drug combination: example of amodiaquine/suplhadoxine-pyrimethamine among children in rural Senegal. Souares A, Lalou R, Sene I, Sow D, Le Hesran J, Malar J 2009 8 118 10.1186/1475-2875-8-118 19497103
30. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Bell D, Wootton D, Mavuto M, Montgomery J, Kayange M, Malar J 2009 8 204 10.1186/1475-2875-8-204 19709418
31. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomized controlled trial. Rahman MM, Dondorp AM, Day NPJ, Lindegardh N, Imwong M, Trans R Soc Trop Med Hyg 2008 102 861 867 10.1016/j.trstmh.2008.05.022 18606428
32. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomized trial. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferrdini L, Taylor W, Checci F, Guthmann JP, Lancet 2005 365 1467 1473 10.1016/S0140-6736(05)66416- 1 15850630 (Pubitemid 40591691)
33. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP, Am J Trop Med Hyg 2004 71 525 530 15569777 (Pubitemid 39601144)
34. Adherence to antimalarial combination therapy with sulfadoxine- pyrimethamine and artesunate in rural Tanzania. Kachur P, Khatib RA, Kaizer E, Fox SS, Abdulla SM, Bloland PB, Am J Trop Med Hyg 2004 71 715 722 15642960 (Pubitemid 40075619)
35. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Depoortere E, Guthman J, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, Legros D, Trop Med Int Health 2004 9 62 67 10.1046/j.1365-3156.2003.01157.x 14728608 (Pubitemid 38178013)
36. Adherence to Medication. Osterberg L, Blaschke T, N Engl J Med 2005 353 487 497 10.1056/NEJMra050100 16079372 (Pubitemid 41127293)
37. Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region. Lemma H, Löfgren C, San Sebastian M, Ethiopia Malar J 2011 10 349
38. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, Ali D, Kachur SP, Mathanga DP, Skarbinski J, Clin Infect Dis 2011 53 772 779 10.1093/cid/cir498 21921220
39. Use of drugs, perceived drug efficacy and preferred providers for febrile children: implications for home management of fever. Rutebemberwa E, Pariyo G, Peterson S, Tomson G, Kallander K, Malar J 2009 8 131 10.1186/1475-2875-8-131 19523220
40. Fever treatment and household wealth: the challenge posed for rolling out combination therapy for malaria. Njau JD, Goodman C, Kachur SP, Palmer N, Khatib RA, Abdulla S, Mills A, Bloland PB, Trop Med Int Health 2006 11 299 313 10.1111/j.1365-3156.2006.01569.x 16553910 (Pubitemid 43357053)
41. Countering drug resistance in the developing world: An assessment of incentives across the value chain and recommendations for policy interventions. Yadav P, Center for Global Development, Working Paper 183 2009 http://www.cgdev.org/content/publications/detail/1422842 Accessed 11 May 2011
42. Uganda Malaria Indicator Survey 2009. Uganda Bureau of Statistics (UBOS) and ICF Macro, Calverton, Maryland, USA: UBOS and ICF Macro 2010
43. Household Survey Report (Baseline) Republic of Uganda -03/09-04/09. ACT Watch-Evidence for Malaria Medicines Policy, 2009 http://www.actwatch.info Accessed 9 May 2011
44. Estimating Benchmarks of Success in the Affordable Medicines Facility - malaria (AMFm) Phase 1. Schaferhoff M, Yamey G, 2011 http://www.seekdevelopment. org/e2pi-estimating-benchmarks-in-amfm-report-en.pdf Accessed November 15, 2011
45. Roll Back Malaria ACT Pricing Fact Sheet. Global Fund to Fight AIDS, TB and Malaria, 2011 http://www.theglobalfund.org/en/amfm Accessed 16 November 2011
46. Coartem International Package Leaflet. Novartis, 2009 http://www.coartem.com/downloads/IPL-Coartem.pdf Accessed 16 November 2011
47. In pursuit of balance: randomization in practice in development field experiments. Bruhn M, McKenzie D, Amer Econ J: Applied Econ 2009 1 200 232 10.1257/app.1.4.200
48. The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: A cluster randomized controlled trial. Kangwana B, Kedenge S, Noor A, Alegana V, Nyandigisi A, Pandit J, Fegan GW, Todd JE, Brooker S, Snow RW, Goodman CA, PLoS Med 2011 8 1000437 10.1371/journal.pmed.1000437 21655317
49. CHAI Operational Research Study Matrix for the Affordable Medicines Facility for Malaria Ad Hoc Committee Meeting. Clinton Health Access Initiative, 2011 Submitted by the Clinton Health Access Initiative and annexed in the AMFm AHC Report